Drug Policy Archives - Page 6 of 55

Washington has a chance to examine ibogaine-assisted therapy benefits

Testimony by Madison Carlino

Psychedelics Policy Newsletter: States propose legalization, optimism for Trump administration nominee, and more

Psychedelics Policy Newsletter by Gregory Ferenstein

State psychedelics legalization and policy roundup — February 2025

Commentary by Gregory Ferenstein

Model legislation for optimal state regulation of hemp cannabinoids

Commentary by Michelle Minton and Geoffrey Lawrence

DEA’s increased DMT quota signals positive advancement in psychedelic research

Commentary by Madison Carlino

Rethinking the need for double-blind placebo trials in psychedelic clinical investigations

Commentary by Madison Carlino

Psychedelic treatment for neurodegenerative disorders

Policy Brief by Madison Carlino

Psychedelic therapy offers possible new hope for Alzheimer’s disease sufferers

Commentary by Madison Carlino

Nonconsensual drug testing raises serious ethical concerns

Commentary by Layal Bou Harfouch

More Drug Policy